---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110848"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:09:25.454542+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cellectar Q3 net loss $4.4M ($1.41/sh); cash $12.6M; progress on EU conditional marketing for iopofosine

## Summary
- Net loss narrowed to $4.4M ($1.41/sh) from $14.7M ($11.18/sh) YoY; R&D spending fell to $2.5M.
- Cash $12.6M at Sep 30, plus $5.8M from Oct warrant exercises; runway into Q3 2026.
- EMA SAWP confirmed iopofosine I 131 may qualify for Conditional Marketing Approval in WM; submission planned 2026.
- Phase 1b of CLR 125 (Auger-emitter) for triple-negative breast cancer initiated; RPDD granted for iopofosine in pediatric high-grade glioma.
- Raised ~$12.7M in Q3; funds to advance TNBC study and EMA application.

## SEC filing metadata
- accession: 0001104659-25-110848
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465925110848/0001104659-25-110848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465925110848/tm2531151d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110848
- JSON: https://secwatch.observer/filing/0001104659-25-110848.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.